79295820 - ITM

Information

• Trademark
• 79295820

• Source

• Serial Number

  79295820

• Registration Number

  6383044

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  July 28, 2020
  3 years ago

• Registration Date

  June 15, 2021
  3 years ago

• Transaction Date

  November 27, 2021
  2 years ago

• Status Date

  June 15, 2021
  3 years ago

• Published for Opposition Date

  March 30, 2021
  3 years ago

• Location Date

  June 15, 2021
  3 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  BHUPATHI, TARA LUISE

• Attorney Docket Number

  540.321US

  Attorney Name

  Kari Moyer-Henry

  Law Office Assigned Location Code

  N60

• Owners

  • Isotopen Technologien Munchen AG
  • ITM Isotope Technologies Munich SE

Case File Statements

• DM0000: The mark consists of "ITM" in stylized form with two circles emanating from the left corner of the "I" in "ITM" at a diagonal.
• GS0051: Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases
• GS0101: Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes
• GS0421: Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]
• GS0441: Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Case File Event Statements

• 11/26/2021 - 2 years ago

  35 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH

• 11/15/2021 - 2 years ago

  34 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 10/21/2021 - 2 years ago

  33 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 9/30/2021 - 2 years ago

  32 - GENERIC MADRID TRANSACTION SENT TO IB Type: XXSS

• 9/30/2021 - 2 years ago

  31 - GENERIC MADRID TRANSACTION CREATED Type: XXCR

• 9/15/2021 - 2 years ago

  30 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 6/15/2021 - 3 years ago

  29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 4/5/2021 - 3 years ago

  28 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 3/30/2021 - 3 years ago

  27 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 3/30/2021 - 3 years ago

  26 - PUBLISHED FOR OPPOSITION Type: PUBO

• 3/15/2021 - 3 years ago

  25 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 3/10/2021 - 3 years ago

  24 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 3/10/2021 - 3 years ago

  23 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 2/23/2021 - 3 years ago

  22 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 2/23/2021 - 3 years ago

  21 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 2/23/2021 - 3 years ago

  20 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 2/23/2021 - 3 years ago

  19 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 2/23/2021 - 3 years ago

  18 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 2/12/2021 - 3 years ago

  17 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 2/12/2021 - 3 years ago

  16 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 2/12/2021 - 3 years ago

  15 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 2/12/2021 - 3 years ago

  14 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 2/12/2021 - 3 years ago

  13 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 2/14/2021 - 3 years ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 2/12/2021 - 3 years ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 2/12/2021 - 3 years ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 12/27/2020 - 3 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 12/8/2020 - 3 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 12/8/2020 - 3 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 11/20/2020 - 3 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 11/19/2020 - 3 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 11/16/2020 - 3 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 10/23/2020 - 3 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 10/19/2020 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 10/15/2020 - 3 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR